Results 21 to 30 of about 21,053 (285)

Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban

Scientific Reports, 2023
Since SLCO1B1 encodes the uptake transporter OATP1B1, which can influence the pharmacokinetic and pharmacodynamic profiles of edoxaban, polymorphisms in SLCO1B1 may affect the edoxaban response.
Ji Min Han, Eun Jeong Jang, Jeong Yee, Tae-Jin Song, Dong-Hyeok Kim, Junbeom Park, Hye Sun Gwak   +6 more
doaj   +2 more sources

Postoperative D-dimer as a signal of venous thromboembolism in patients receiving Edoxaban after hip or knee arthroplasty [PDF]

Journal of Pharmaceutical Health Care and Sciences
Background Edoxaban is the only direct-acting oral anticoagulant (DOAC) indicated for preventing venous thromboembolism (VTE) in patients undergoing arthroplasty and can be administered for a short period (1–2 weeks).
Norito Nishiyama, Shiori Iwane, Masayuki Tanaka, Takanori Saito, Toshikazu Tsuji, Noboru Tanigawa   +5 more
doaj   +2 more sources

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. [PDF]

European Heart Journal, 2019
AIMS: Edoxaban is a direct factor Xa inhibitor approved for stroke prevention in atrial fibrillation (AF). Uninterrupted edoxaban therapy in patients undergoing AF ablation has not been tested. METHODS AND RESULTS: The ELIMINATE-AF trial, a multinational,
Abozguia, K, Camm, J, Cappato, R, Diener, H-C, Grimaldi, M, Heidbüchel, H, Hohnloser, SH, Kautzner, J, Mont, L, Morillo, CA, Mönninghoff, C, Rauer, H, Reimitz, P-E, Smolnik, R   +13 more
core   +3 more sources

Prolonged Edoxaban in Patients With Low Body Weight and Cancer-Associated Isolated Distal Deep Vein Thrombosis [PDF]

JACC: Advances
Background: The ONCO DVT study revealed that 12-month edoxaban treatment for cancer-associated isolated distal deep vein thrombosis (IDDVT) was superior to 3-month edoxaban treatment.
Tomoyuki Nagai, MD, Naohiko Nakanishi, MD, Yugo Yamashita, MD, Takeshi Morimoto, MPH, MD, Nao Muraoka, MD, Michihisa Umetsu, MD, Yuji Nishimoto, MD, Takuma Takada, MD, Yoshito Ogihara, MD, Tatsuya Nishikawa, MD, Nobutaka Ikeda, MD, Kazunori Otsui, MD, Daisuke Sueta, MD, Yukari Tsubata, MD, Masaaki Shoji, MD, Ayumi Shikama, MD, Yutaka Hosoi, MD, Yasuhiro Tanabe, MD, Ryuki Chatani, MD, Kengo Tsukahara, MD, Kitae Kim, MD, Satoshi Ikeda, MD, Takeshi Kimura, MD, Satoaki Matoba, MD   +23 more
doaj   +2 more sources

Edoxaban [PDF]

Reactions Weekly, 2018
Ein weiteres «direktes» orales Antikoagulans, das weniger Blutungen verursacht als Warfarin. In welchem Ausmass sich die Studienresultate auf einen Vergleich mit dem in der Schweiz gebräuchlichen Phenprocoumon extrapolieren lassen, ist nicht klar.
Lenka Špinarová, Jindřich Špinar, Růžena Lábrová   +2 more
  +6 more sources

Very Elderly Patients With Atrial Fibrillation Treated With Edoxaban

JACC: Advances, 2023
Gentian Denas, Giacomo Zoppellaro, Serena Granziera, Leopoldo Pagliani, Franco Noventa, Sabino Iliceto, Vittorio Pengo   +6 more
openalex   +2 more sources

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

New England Journal of Medicine, 2013
Harry R Büller, Saskia Middeldorp, Peter Verhamme   +2 more
exaly   +2 more sources

Intracerebral Hemorrhage During the Chronic Phase of Eosinophilic Granulomatosis With Polyangiitis: A Case Report Emphasizing Cerebrovascular Vulnerability. [PDF]

Clin Case Rep
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of small‐vessel vasculitis typically associated with eosinophilia, asthma, and systemic inflammation. Although peripheral neuropathies are relatively common, central nervous system involvement, especially intracerebral hemorrhage during the remission phase of EGPA, is uncommon,
Watanabe S, Kasuya M, Shibata Y.
europepmc   +2 more sources

Edoxaban [PDF]

Hospital Pharmacy, 2015
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada, Danial E, Baker, Kyle, Ingram   +2 more
openaire   +3 more sources

Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation

Frontiers in Pharmacology, 2021
Background and Purpose: Edoxaban exposure varies across different ethnicities. The purpose of our study was to examine the risk factors associated with high or low edoxaban concentrations in Asian populations.Methods: Participants with atrial ...
Shin-Yi Lin, Shin-Yi Lin, Ching-Hua Kuo, Li-Ting Ho, Yen-Bin Liu, Chih-Fen Huang, Chih-Fen Huang, Sung-Chun Tang, Jiann-Shing Jeng   +8 more
doaj   +1 more source